Autopsy report · NCT04886063

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

“ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 4 months before it stopped.
• 423 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

LeonaBio

Sponsor type

Industry

Conditions

Alzheimer Disease

Interventions

ATH-1017

Participants

423

Sites

1

Countries

United States

Trials that died the same way

• Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
  “The study was terminated as its Part A did not meet the primary endpoint.” (57% match in meaning)
• Long-Term Follow-Up Study of Patients Receiving ATL001
  “The long-term follow-up of patients is being migrated to the original (parent) study protocols (Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474). Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.